Monge Marta, Colas Eva, Doll Andreas, Gonzalez Marta, Gil-Moreno Antonio, Planaguma Jesus, Quiles Maite, Arbos Maria Antonia, Garcia Angel, Castellvi Josep, Llaurado Marta, Rigau Marina, Alazzouzi Hafid, Xercavins Jordi, Alameda Francesc, Reventos Jaume, Abal Miguel
Research Institute Vall d'Hebron University Hospital, Department of Gynecological Oncology, Vall d'Hebron University Hospital, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Cancer Res. 2007 Jul 15;67(14):6753-9. doi: 10.1158/0008-5472.CAN-06-4487.
We have described recently the Ets family transcription factor, ERM/ETV5, specifically up-regulated in endometrioid endometrial carcinoma (EEC) and associated with myometrial infiltration. Ets family members have been correlated to tumor progression by up-regulating the expression of matrix-degrading proteases. In the present study, we investigated the possibility that in EEC, ERM/ETV5 may act by inducing the expression of genes involved in extracellular matrix remodeling. Unraveling the molecular events associated with the initiation of tumor invasion would represent an obvious improvement for EEC patients. The overexpression of ERM/ETV5 induced scattering in the endometrial cancer cell line Hec-1A, correlating to increased matrix metalloproteinase-2 (MMP-2) gelatinase activity. Both chromatin immunoprecipitation and reversion experiments with RNA interference and specific MMP-2 inhibitor showed a functional link between ERM/ETV5 overexpression and MMP-2 activation. The increased MMP-2 activity associated with overexpressed ERM/ETV5 in a mouse model conferred invasive capacity to endometrial tumors. Orthotopically implanted overexpressing ERM/ETV5 tumors presented a more aggressive and infiltrative pattern of myometrial invasion. Finally, the specific localization of ERM/ETV5 and MMP-2 at the invasive front of myometrial infiltrating human endometrial carcinomas further reinforced the hypothesis of a role for ERM/ETV5 in the early steps of endometrial dissemination. Taken together, these results lead us to propose that in EEC, ERM/ETV5 acts through MMP-2 gelatinolytic activity to confer invasive capabilities, associated with an initial switch to myometrial infiltration. They also postulate ERM/ETV5 as a valuable marker for patient stratification and a transcription pathway that should be evaluated for therapies specifically targeting the initial steps of EEC dissemination.
我们最近描述了Ets家族转录因子ERM/ETV5,其在子宫内膜样腺癌(EEC)中特异性上调,并与肌层浸润相关。Ets家族成员通过上调基质降解蛋白酶的表达与肿瘤进展相关。在本研究中,我们调查了在EEC中ERM/ETV5可能通过诱导参与细胞外基质重塑的基因表达发挥作用的可能性。阐明与肿瘤侵袭起始相关的分子事件对EEC患者而言将是一项显著的进展。ERM/ETV5的过表达诱导子宫内膜癌细胞系Hec-1A发生散射,这与基质金属蛋白酶-2(MMP-2)明胶酶活性增加相关。染色质免疫沉淀以及RNA干扰和特异性MMP-2抑制剂的回复实验均显示ERM/ETV5过表达与MMP-2激活之间存在功能联系。在小鼠模型中,与过表达的ERM/ETV5相关的MMP-2活性增加赋予子宫内膜肿瘤侵袭能力。原位植入过表达ERM/ETV5的肿瘤呈现出更具侵袭性和浸润性的肌层侵袭模式。最后,ERM/ETV5和MMP-2在人子宫内膜癌肌层浸润的侵袭前沿的特异性定位进一步强化了ERM/ETV5在子宫内膜播散早期步骤中发挥作用的假说。综上所述,这些结果使我们提出,在EEC中,ERM/ETV5通过MMP-2的明胶溶解活性发挥作用以赋予侵袭能力,这与向肌层浸润的初始转变相关。它们还假定ERM/ETV5是用于患者分层的有价值标志物以及一条转录途径,该途径应针对专门靶向EEC播散初始步骤的疗法进行评估。